Medpace(MEDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MEDP Medpace

Trading 04-01 10:53:47 EDT

488.58

+8.39

+1.75%

High490.24	Low483.16	Vol35.06K
Open485.36	D1 Closing480.19	Amplitude1.47%
Mkt Cap13.87B	Tradable Cap10.86B	Total Shares28.38M
T/O17.09M	T/O Rate0.16%	Tradable Shares22.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MEDP","market":"US","secType":"STK","nameCN":"Medpace","latestPrice":488.575,"timestamp":1775055224235,"preClose":480.19,"halted":0,"volume":35057,"delay":0,"changeRate":0.017461838022449428,"floatShares":22220178,"shares":28381283,"eps":15.28,"marketStatus":"Trading","change":8.385,"latestTime":"04-01 10:53:47 EDT","open":485.36,"high":490.24,"low":483.16,"amount":17086967.6021,"amplitude":0.014744,"askPrice":489.74,"askSize":5,"bidPrice":488.28,"bidSize":10,"shortable":3,"etf":0,"ttmEps":15.28,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775073600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":480.19,"preHourTrading":{"tag":"盘前","latestPrice":480,"preClose":480.19,"latestTime":"09:09 EDT","volume":9,"amount":4318.62012,"timestamp":1775048959397,"change":-0.19,"changeRate":-0.000396,"amplitude":0.002416},"postHourTrading":{"tag":"盘后","latestPrice":480.57,"preClose":480.19,"latestTime":"18:53 EDT","volume":4436,"amount":2130203.567,"timestamp":1774997623177,"change":0.38,"changeRate":0.000791,"amplitude":0.000854},"volumeRatio":0.583853,"impliedVol":0.5589,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/MEDP","defaultTab":"news","newsList":[{"id":"2622879479","title":"New Medpace-Backed PET Tracer Study Targets Precision Cancer Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879479?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:37","pubTimestamp":1774629455,"startTime":"0","endTime":"0","summary":"Medpace Holdings Inc ($MEDP) announced an update on their ongoing clinical study. The Phase 1/2 study “A Phase 1/2 Study of [18F]FPyQCP for PET Ima...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-medpace-backed-pet-tracer-study-targets-precision-cancer-imaging?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-medpace-backed-pet-tracer-study-targets-precision-cancer-imaging?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU2065169927.USD","LU2065170008.USD","BK4588","MEDP","BK4121","LU2065171402.SGD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622393883","title":"A Look At Medpace Holdings (MEDP) Valuation After Strong Recent Shareholder Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2622393883","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622393883?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:09","pubTimestamp":1774476573,"startTime":"0","endTime":"0","summary":"Recent returns and current snapshot\nMedpace Holdings (MEDP) has delivered a 1 day return of 1.3% and about 2.6% over the past week, with a month gain of roughly 4.9% and a past 3 months return of 18.4%.\nOver longer horizons, total returns stand at about 47.0% for the past year, around 1.5x over three years, and roughly 1.8x over five years, against a recent close of US$466.80.\nSee our latest analysis for Medpace Holdings.\nMEDP's recent share price moves, including a 4.9% 1 month share price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/a-look-at-medpace-holdings-medp-valuation-after-strong-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/a-look-at-medpace-holdings-medp-valuation-after-strong-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","BK4585","LU2065170008.USD","BK4121","BK4588","MEDP","LU2065171402.SGD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622042128","title":"Zelluna FY2025 annual report published; cash and cash equivalents climb to NOK 78 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622042128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622042128?lang=en_us&edition=fundamental","pubTime":"2026-03-25 14:28","pubTimestamp":1774420086,"startTime":"0","endTime":"0","summary":"Zelluna’s annual report outlines progress toward first-in-human testing of its TCR-NK platform, with the lead program ZI-MA4-1 advancing through GMP manufacturing and clinical trial preparations.The company submitted a UK clinical trial application for ZI-MA4-1 in December 2025, which was later approved in February 2026.It entered a clinical partnership with Medpace in February 2026 to support the Phase 1 ZIMA-101 trial in advanced solid cancers, with initial clinical data expected from mid-2026.In FY2025, total operating expenses rose to NOK 144 million and loss widened to NOK 141 million.Zelluna ended FY2025 with NOK 78 million in cash and cash equivalents, up due to two private placements and cash acquired through the business combination completed in March 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL3XxLmx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","BK4585","BK4588","LU2065169927.USD","LU2065171402.SGD","MEDP","LU2065171311.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622018273","title":"Medpace to report first-quarter 2026 results and host earnings call","url":"https://stock-news.laohu8.com/highlight/detail?id=2622018273","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622018273?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:05","pubTimestamp":1774382717,"startTime":"0","endTime":"0","summary":"Medpace will report financial results on April 22, 2026, after the market close.A conference call to discuss the results is scheduled for April 23, 2026, at 9:00 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire  on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL23XD6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","BK4585","MEDP","LU2065169927.USD","LU2065171402.SGD","LU2065171311.SGD","BK4121","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622018272","title":"Press Release: Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622018272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622018272?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:05","pubTimestamp":1774382700,"startTime":"0","endTime":"0","summary":"Medpace Holdings, Inc.   today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results.A supplemental slide presentation will also be available at the \"Investors\" section of Medpace's website prior to the start of the call.Medpace is a scientifically-driven, global, full-service clinical contract research organization  providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. He","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065171311.SGD","LU2065170008.USD","LU2065171402.SGD","BK4588","BK4121","MEDP","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620206853","title":"Top Medpace Executive Makes Major Move With High-Value Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206853","media":"TIPRANKS","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206853?lang=en_us&edition=fundamental","pubTime":"2026-03-20 10:07","pubTimestamp":1773972456,"startTime":"0","endTime":"0","summary":"New insider activity at Medpace Holdings ( ($MEDP) ) has taken place on March 19, 2026. Medpace Holdings has seen notable insider activity as Presi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-medpace-executive-makes-major-move-with-high-value-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-medpace-executive-makes-major-move-with-high-value-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","MEDP","BK4588","BK4121","LU2065170008.USD","LU2065169927.USD","BK4585","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620797012","title":"Medpace President Jesse J. Geiger disposes of USD 14.44 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620797012","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620797012?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:46","pubTimestamp":1773953185,"startTime":"0","endTime":"0","summary":"Medpace President Jesse Geiger reported exercising employee stock options for 31,707 common shares at USD 138.87 per share.He also reported selling 31,707 common shares at an average price of USD 455.3 per share.Following the transactions, Geiger beneficially owned 15,000 Medpace common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Yz7b5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medpace President Jesse J. Geiger disposes of USD 14.44 million in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","MEDP","LU2065171402.SGD","BK4585","LU2065169927.USD","BK4588","LU2065171311.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620441184","title":"Zelluna selects Medpace as CRO for ZIMA-101 Phase 1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620441184","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620441184?lang=en_us&edition=fundamental","pubTime":"2026-03-17 15:48","pubTimestamp":1773733714,"startTime":"0","endTime":"0","summary":"Zelluna selected Medpace as its contract research organization to support the first-in-human Phase 1 trial of ZI-MA4-1 . Medpace will provide clinical operations and trial management, as well as regulatory support. The study will evaluate safety and early clinical activity in patients with advanced solid cancers. Zelluna said initial clinical data is expected from mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbvtbf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","MEDP","LU2065171402.SGD","BK4585","LU2065169927.USD","BK4588","LU2065171311.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620492581","title":"Medpace Holdings Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620492581","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620492581?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:24","pubTimestamp":1773696280,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7vFBT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4121","LU2065170008.USD","LU2065171402.SGD","MEDP","LU2065171311.SGD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619717105","title":"Is Medpace Holdings (MEDP) Still Appealing After Recent Volatility And Zelluna Partnership Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2619717105","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619717105?lang=en_us&edition=fundamental","pubTime":"2026-03-15 17:24","pubTimestamp":1773566663,"startTime":"0","endTime":"0","summary":"If you are trying to figure out whether Medpace Holdings at around US$450 per share is still good value, you are not alone. This article is written with that question front and center.\nThe stock has had a mixed run recently, with a 4.3% decline over the last 7 days, a 5.2% gain over 30 days, a 21.1% decline year to date, yet a 38.6% return over 1 year and a 156.4% return over 3 years.\nThese moves have kept Medpace on many investors' watchlists, with attention on how its contract research...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-medpace-holdings-medp-still-appealing-after-recent-volati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-medpace-holdings-medp-still-appealing-after-recent-volati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171402.SGD","LU2065171311.SGD","BK4121","BK4585","BK4588","LU2065170008.USD","DCF","MEDP","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635889","title":"Medpace Holdings Raised to Equal-Weight From Underweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617635889?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:15","pubTimestamp":1772806500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MEDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 09:15 ET (14:15 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616324050","title":"Medpace is Differentiated as Most Efficient Contract Research Organization, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616324050?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:57","pubTimestamp":1772553422,"startTime":"0","endTime":"0","summary":"Medpace  is differentiated as the most efficient contract research organization per employee and is positioned to benefit from biopharma end markets expected to see robust clinical trial activity, RBC Capital Markets said in a Monday research report.The company's growing efficiency is a byproduct of investment in training and prudent hiring in recent years. Any increase in hiring could be a safe indicator of steady demand signals, according to the note.The recent uptick in trial cancellations looks transitory, not structural, and is more suspension-focused while terminations trended downward, according to RBC.The brokerage said it initiated coverage of the stock with an outperform rating and a price target of $522 per share.Price: 448.58, Change: -8.89, Percent Change: -1.94","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","MEDP","LU2065171402.SGD","BK4585","LU2065170008.USD","BK4588","LU2065171311.SGD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616932454","title":"Medpace Holdings Initiated at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2616932454","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616932454?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:33","pubTimestamp":1772551980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MEDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 10:33 ET (15:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616341747","title":"RBC Initiates Medpace Holdings at Outperform With $522 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616341747","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616341747?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:33","pubTimestamp":1772537599,"startTime":"0","endTime":"0","summary":"Medpace Holdings (MEDP) has an average rating of hold and mean price target of $503, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616393138","title":"Medpace initiated with an Outperform at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2616393138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616393138?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:40","pubTimestamp":1772498410,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Ryan Halsted initiated coverage of Medpace (MEDP) with an Outperform rating and $522 price target The company is the most effic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medpace-initiated-with-an-outperform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medpace-initiated-with-an-outperform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612944913","title":"Levi & Korsinsky Probes Medpace Holdings Over Securities Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2612944913","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612944913?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:02","pubTimestamp":1771423350,"startTime":"0","endTime":"0","summary":"Levi & Korsinsky has opened an investigation into Medpace Holdings over potential securities law claims, focusing on whether the company misrepresented the health of its clinical-trial bookings pipeline amid elevated cancellations and a weakening book-to-bill ratio. The probe follows Medpace’s disclosure of a Q4 2025 book-to-bill ratio of 1.04 and a subsequent share-price drop of about 15.9%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL81sXV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4585","MEDP","LU2065169927.USD","BK4588","BK4121","LU2065171311.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612448554","title":"Medpace Holdings Inc : TD Cowen Raises to Hold From Sell; Cuts Target Price to $419 From $462","url":"https://stock-news.laohu8.com/highlight/detail?id=2612448554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612448554?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:01","pubTimestamp":1771416091,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZE0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4121","LU2065171311.SGD","MEDP","LU2065170008.USD","LU2065171402.SGD","BK4585","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612307417","title":"Medpace upgraded to Hold from Sell at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2612307417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612307417?lang=en_us&edition=fundamental","pubTime":"2026-02-18 18:55","pubTimestamp":1771412116,"startTime":"0","endTime":"0","summary":"TD Cowen upgraded Medpace (MEDP) to Hold from Sell with a price target of $419, down from $462. The shares have re-rated from a peak multiple and n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medpace-upgraded-to-hold-from-sell-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medpace-upgraded-to-hold-from-sell-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","MEDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611412228","title":"Pinterest, DraftKings, And Flutter Are Among Top 10 Large Cap Losers Last Week (Feb. 9-Feb. 13): Are the Others in Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2611412228","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611412228?lang=en_us&edition=fundamental","pubTime":"2026-02-15 21:32","pubTimestamp":1771162320,"startTime":"0","endTime":"0","summary":"Pinterest, DraftKings, and Astera Labs led last week's large-cap losers as cautious outlooks and post-earnings guidance/downgrades sparked a broad pullback across tech, housing, and gaming names.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/15/Spokane--Wa---usa---June-2020-View-Of-Dr.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/15/Spokane--Wa---usa---June-2020-View-Of-Dr.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/02/50634529/pinterest-draftkings-and-flutter-are-among-top-10-large-cap-losers-last-week-feb-9-feb-13-are-the-others-in-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/02/50634529/pinterest-draftkings-and-flutter-are-among-top-10-large-cap-losers-last-week-feb-9-feb-13-are-the-others-in-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4150","LU1496350171.SGD","LU2065170008.USD","IE0009354923.USD","LU0575583348.USD","LU0130102774.USD","BK4551","BK4585","SGXZ51526630.SGD","LU2931357623.SGD","DKNG","BK4121","LU0154245673.USD","LABX","LU0320765489.SGD","LU2065169927.USD","LU0208291251.USD","BK4173","LU1015430645.USD","BK4187","LU1201861249.SGD","BK4079","LU2065171311.SGD","LU0477156953.USD","SG9999004253.SGD","BK4588","LU2089985449.USD","SGXZ99366536.SGD","LU0980610538.SGD","LU0130517989.USD","FLUT","LU2065171402.SGD","MEDP","LU0070302665.USD","LU2290526834.HKD","LU0648001328.SGD","KRMN","BK4539","RYAN","SGXZ81514606.USD","LU2360107168.USD","BK4141","LU0154245756.USD","SG9999001077.SGD","LU1496350502.SGD","Z","BK4089","LU0274383776.USD","PINS","CBRE","BK4548","LU1861215975.USD","LU1861220033.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2611198569","title":"Medpace Holdings Raised to Buy From Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2611198569","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611198569?lang=en_us&edition=fundamental","pubTime":"2026-02-14 04:36","pubTimestamp":1771014960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MEDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 15:36 ET (20:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medpace.com","stockEarnings":[{"period":"1week","weight":0.0422},{"period":"1month","weight":0.0629},{"period":"3month","weight":-0.145},{"period":"6month","weight":-0.1044},{"period":"1year","weight":0.576},{"period":"ytd","weight":-0.145}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.052},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0282},{"period":"1year","weight":0.1626},{"period":"ytd","weight":-0.0463}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.006402},{"month":2,"riseRate":0.3,"avgChangeRate":-0.035449},{"month":3,"riseRate":0.7,"avgChangeRate":0.006916},{"month":4,"riseRate":0.666667,"avgChangeRate":0.005652},{"month":5,"riseRate":0.444444,"avgChangeRate":0.020283},{"month":6,"riseRate":1,"avgChangeRate":0.07437},{"month":7,"riseRate":0.666667,"avgChangeRate":0.148095},{"month":8,"riseRate":0.666667,"avgChangeRate":0.032832},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004448},{"month":10,"riseRate":0.5,"avgChangeRate":0.057543},{"month":11,"riseRate":0.7,"avgChangeRate":0.057867},{"month":12,"riseRate":0.7,"avgChangeRate":0.025222}],"exchange":"NASDAQ","name":"Medpace","nameEN":"Medpace"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Medpace(MEDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Medpace(MEDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Medpace,MEDP,Medpace股票,Medpace股票老虎,Medpace股票老虎国际,Medpace行情,Medpace股票行情,Medpace股价,Medpace股市,Medpace股票价格,Medpace股票交易,Medpace股票购买,Medpace股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Medpace(MEDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Medpace(MEDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}